Notícias Corvus Pharmaceuticals Inc - CRVS | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Corvus Pharmaceuticals Inc (CRVS)
Corvus Pharmaceuticals Inc (CRVS) Notícias

Corvus Pharmaceuticals Inc (CRVS)

5,09

0,39

(8,30%)

No fechamento: 19 Dezembro 6:00PM

Atrasado por 15 minutos

5,0855

-0,0045

( -0,09% )

Após o horário de negociação: 8:04PM

Atrasado por 15 minutos

Discussões em tempo real e ideias de negociação: Negocie com confiança com nossa poderosa plataforma.

Form 8-K - Current report

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Form 8-K - Current report

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Corvus Pharmaceuticals

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições